Insider Buy/Sell Details for the Biotechnology Industry — January 2026
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1179)
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
629
Price
$484.99
Total Value
$305.06K
Shares Held After
5,133
% of Holdings
10.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
375
Price
$483.80
Total Value
$181.43K
Shares Held After
5,762
% of Holdings
6.1%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
471
Price
$482.72
Total Value
$227.36K
Shares Held After
6,137
% of Holdings
7.1%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
891
Price
$481.86
Total Value
$429.34K
Shares Held After
6,608
% of Holdings
11.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
376
Price
$480.68
Total Value
$180.74K
Shares Held After
7,499
% of Holdings
4.8%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
797
Price
$494.27
Total Value
$393.94K
Shares Held After
0
% of Holdings
100.0%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
374
Price
$493.47
Total Value
$184.56K
Shares Held After
797
% of Holdings
31.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,110
Price
$492.44
Total Value
$546.61K
Shares Held After
1,171
% of Holdings
48.7%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,201
Price
$491.35
Total Value
$590.11K
Shares Held After
2,281
% of Holdings
34.5%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,659
Price
$490.11
Total Value
$813.09K
Shares Held After
3,482
% of Holdings
32.3%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
677
Price
$489.49
Total Value
$331.38K
Shares Held After
5,141
% of Holdings
11.6%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,189
Price
$488.38
Total Value
$580.68K
Shares Held After
5,818
% of Holdings
17.0%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
856
Price
$487.40
Total Value
$417.22K
Shares Held After
7,007
% of Holdings
10.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,669
Price
$486.05
Total Value
$811.22K
Shares Held After
7,863
% of Holdings
17.5%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,169
Price
$485.00
Total Value
$566.96K
Shares Held After
9,532
% of Holdings
10.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
697
Price
$483.80
Total Value
$337.21K
Shares Held After
10,701
% of Holdings
6.1%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
873
Price
$482.72
Total Value
$421.41K
Shares Held After
11,398
% of Holdings
7.1%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,657
Price
$481.86
Total Value
$798.45K
Shares Held After
12,271
% of Holdings
11.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
697
Price
$480.68
Total Value
$335.04K
Shares Held After
13,928
% of Holdings
4.8%
RECURSION PHARMACEUTICALS, INC. (RXRX)
Gibson Christopher — Director
Shares
40,000
Price
$4.25
Total Value
$170.00K
Shares Held After
933,839
% of Holdings
4.1%
Crinetics Pharmaceuticals, Inc. (CRNX)
Kalofonos Isabel — Chief Commercial Officer
Shares
2,500
Price
$55.00
Total Value
$137.50K
Shares Held After
834
% of Holdings
75.0%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
1,337
Price
$98.52
Total Value
$131.72K
Shares Held After
288,172
% of Holdings
0.5%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
8,147
Price
$97.96
Total Value
$798.08K
Shares Held After
289,509
% of Holdings
2.7%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
4,727
Price
$96.85
Total Value
$457.81K
Shares Held After
297,656
% of Holdings
1.6%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
317
Price
$98.52
Total Value
$31.23K
Shares Held After
84,914
% of Holdings
0.4%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
1,929
Price
$97.96
Total Value
$188.96K
Shares Held After
85,231
% of Holdings
2.2%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
1,119
Price
$96.85
Total Value
$108.38K
Shares Held After
87,160
% of Holdings
1.3%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
317
Price
$98.52
Total Value
$31.23K
Shares Held After
58,311
% of Holdings
0.5%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
1,929
Price
$97.96
Total Value
$188.96K
Shares Held After
58,628
% of Holdings
3.2%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
1,119
Price
$96.85
Total Value
$108.38K
Shares Held After
60,557
% of Holdings
1.8%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
326
Price
$98.52
Total Value
$32.12K
Shares Held After
44,723
% of Holdings
0.7%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
1,987
Price
$97.96
Total Value
$194.65K
Shares Held After
45,049
% of Holdings
4.2%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
1,153
Price
$96.85
Total Value
$111.67K
Shares Held After
47,036
% of Holdings
2.4%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
317
Price
$98.52
Total Value
$31.23K
Shares Held After
43,798
% of Holdings
0.7%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
1,929
Price
$97.96
Total Value
$188.96K
Shares Held After
44,115
% of Holdings
4.2%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
1,119
Price
$96.85
Total Value
$108.38K
Shares Held After
46,044
% of Holdings
2.4%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
186
Price
$98.52
Total Value
$18.32K
Shares Held After
68,552
% of Holdings
0.3%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
1,137
Price
$97.96
Total Value
$111.38K
Shares Held After
68,738
% of Holdings
1.6%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
660
Price
$96.85
Total Value
$63.92K
Shares Held After
69,875
% of Holdings
0.9%
Axsome Therapeutics, Inc. (AXSM)
TABUTEAU HERRIOT — Director
Shares
78,703
Price
$171.28
Total Value
$13.48M
Shares Held After
7,229
% of Holdings
91.6%
Acumen Pharmaceuticals, Inc. (ABOS)
Siemers Eric — Chief Medical Officer
Shares
4,000
Price
$1.96
Total Value
$7.83K
Shares Held After
166,298
% of Holdings
2.3%
Acumen Pharmaceuticals, Inc. (ABOS)
OConnell Daniel Joseph — Director
Shares
4,649
Price
$1.97
Total Value
$9.16K
Shares Held After
662,839
% of Holdings
0.7%
Acumen Pharmaceuticals, Inc. (ABOS)
Meisner Derek M — Chief Legal Officer & Corp Sec
Shares
4,000
Price
$1.96
Total Value
$7.84K
Shares Held After
157,127
% of Holdings
2.5%
Acumen Pharmaceuticals, Inc. (ABOS)
Zuga Matt — CFO & Chief Business Officer
Shares
4,000
Price
$1.96
Total Value
$7.84K
Shares Held After
227,744
% of Holdings
1.7%
Acumen Pharmaceuticals, Inc. (ABOS)
Barton Russell — Chief Operating Officer
Shares
4,000
Price
$1.96
Total Value
$7.83K
Shares Held After
132,117
% of Holdings
2.9%
Adaptive Biotechnologies Corp (ADPT)
ROBINS CHAD M — Director
Shares
124,998
Price
$15.59
Total Value
$1.95M
Shares Held After
2,584,243
% of Holdings
4.6%
AN2 Therapeutics, Inc. (ANTX)
Eizen Joshua M — Chief Operating Officer and Chief Legal Officer
Shares
17,923
Price
$1.00
Total Value
$17.95K
Shares Held After
159,430
% of Holdings
10.1%
AN2 Therapeutics, Inc. (ANTX)
Chanda Sanjay — Chief Development Officer
Shares
3,295
Price
$1.00
Total Value
$3.30K
Shares Held After
81,779
% of Holdings
3.9%
AN2 Therapeutics, Inc. (ANTX)
Prior Stephen David — Chief Strategy Officer
Shares
3,604
Price
$1.00
Total Value
$3.61K
Shares Held After
61,944
% of Holdings
5.5%
AN2 Therapeutics, Inc. (ANTX)
Day Lucy — Chief Financial Officer
Shares
3,295
Price
$1.00
Total Value
$3.30K
Shares Held After
80,875
% of Holdings
3.9%
Showing 1001–1050 of 1179 transactions (page 21 of 24)